January 23, 2018
Osaka-based biotech AnGes said on January 22 that it has filed its gene therapy AMG0001 (beperminogene perplasmid) under Japan’s conditional time-limited approval scheme for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. AMG0001,...read more